Loss of exclusivityJanuary 2037latest FDA-listed patent expiry
CompanyChimerix →See this company's full patent-cliff portfolio
Drug detail
Brand name
MODEYSO
Active ingredient
DORDAVIPRONE HYDROCHLORIDE
Strength
EQ 125MG BASE
Dosage form
CAPSULE
Route
ORAL
Modality
Small molecule
FDA approval
August 2025
Marketing status
RX
Listed patents
Patent
Expires
Type
10172862
January 2037
use U-4254
12102639
January 2037
use U-4254
10369154
January 2037
use U-4254
11976068
March 2036
product
9265765
July 2034
product
9629842
April 2032
use U-4254
RE46290
April 2032
use U-4254
Regulatory exclusivity
Code
Expires
ODE-547
August 2032
NCE
August 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.